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Abstract: OBJECTIVES: Primary graft dysfunction (PGD) is a major cause of mortality within the
first year following lung transplantation. Pulmonary hypertension, elevated body mass index (BMI),
prolonged ischaemic time of the graft, intraoperative blood transfusions >1000 ml and the use of car-
diopulmonary bypass or extracorporeal membrane oxygenation increase the risk for PGD. We aimed to
evaluate whether dyslipidaemia is an additional risk factor for the development of PGD. METHODS: We
retrospectively analysed demographic and clinical data of 264 patients who received their first bilateral
lung transplantation between March 2000 and October 2013 at our institution. The endpoint was PGD
grade 3 at any time, defined according to the International Society for Heart and Lung Transplantation
(ISHLT) criteria. Fasting lipid profiles at listing time or just before transplantation (baseline) were doc-
umented and dyslipidaemia was defined as any of the parameters being out of range. Comparisons of
continuous variables between patients with PGD grade 3 and patients without were performed with the
Mann-Whitney U-test, whereas proportions were compared with the ฀(2) test. Continuous variables were
presented as arithmetic means with standard deviation for ease of comparison, but levels of statistical
significance were computed using the appropriate non-parametric statistical test. To identify PGD risk
factors, a forward stepwise logistic regression model was used. RESULTS: PGD occurred in 63 recipi-
ents (24%). Pretransplant dyslipidaemia was documented in 153 recipients (58%) and was significantly
more prevalent among recipients developing PGD (45 vs 108, P < 0.013). Despite various underlying
pulmonary pathologies, higher triglyceride (TG) levels (1.41 ± 0.78 vs 1.16 ± 0.78, P < 0.012), lower
high-density lipoprotein-cholesterol (HDL-C) concentrations (1.24 ± 0.55 vs 1.57 ± 0.71, P < 0.0005)
and higher cholesterol/HDL-C values (3.80 ± 2.02 vs 3.00 ± 0.92, P < 0.0005) were associated with a
lower incidence of PGD. Patients with PGD had significantly longer ischaemic time (350 ± 89 vs 322 ±
91, P = 0.017) and higher BMI (23 ± 5 vs 21 ± 4.4, P < 0.007). CONCLUSION: Dyslipidaemia seems to
be an independent risk factor for PGD after lung transplantation: low circulating levels of HDL-C and
hypertriglyceridaemia increase the incidence of PGD. Even if HDL-C levels are difficult to alter today,
triglyceride and cholesterol levels can be addressed therapeutically and may have a positive influence on
the development of PGD.
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Abstract
OBJECTIVES: Primary graft dysfunction (PGD) is a major cause of mortality within the first year following lung transplantation. Pulmonary
hypertension, elevated body mass index (BMI), prolonged ischaemic time of the graft, intraoperative blood transfusions >1000 ml and the
use of cardiopulmonary bypass or extracorporeal membrane oxygenation increase the risk for PGD. We aimed to evaluate whether dyslipi-
daemia is an additional risk factor for the development of PGD.
METHODS: We retrospectively analysed demographic and clinical data of 264 patients who received their first bilateral lung transplant-
ation between March 2000 and October 2013 at our institution. The endpoint was PGD grade 3 at any time, defined according to the
International Society for Heart and Lung Transplantation (ISHLT) criteria. Fasting lipid profiles at listing time or just before transplantation
(baseline) were documented and dyslipidaemia was defined as any of the parameters being out of range. Comparisons of continuous vari-
ables between patients with PGD grade 3 and patients without were performed with the Mann–Whitney U-test, whereas proportions were
compared with the χ2 test. Continuous variables were presented as arithmetic means with standard deviation for ease of comparison, but
levels of statistical significance were computed using the appropriate non-parametric statistical test. To identify PGD risk factors, a forward
stepwise logistic regression model was used.
RESULTS: PGD occurred in 63 recipients (24%). Pretransplant dyslipidaemia was documented in 153 recipients (58%) and was significantly
more prevalent among recipients developing PGD (45 vs 108, P < 0.013). Despite various underlying pulmonary pathologies, higher triglycer-
ide (TG) levels (1.41 ± 0.78 vs 1.16 ± 0.78, P < 0.012), lower high-density lipoprotein-cholesterol (HDL-C) concentrations (1.24 ± 0.55 vs
1.57 ± 0.71, P < 0.0005) and higher cholesterol/HDL-C values (3.80 ± 2.02 vs 3.00 ± 0.92, P < 0.0005) were associated with a lower incidence of
PGD. Patients with PGD had significantly longer ischaemic time (350 ± 89 vs 322 ± 91, P = 0.017) and higher BMI (23 ± 5 vs 21 ± 4.4, P < 0.007).
CONCLUSIONS: Dyslipidaemia seems to be an independent risk factor for PGD after lung transplantation: low circulating levels of HDL-C
and hypertriglyceridaemia increase the incidence of PGD. Even if HDL-C levels are difficult to alter today, triglyceride and cholesterol levels
can be addressed therapeutically and may have a positive influence on the development of PGD.
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INTRODUCTION
Primary graft dysfunction (PGD) is a major cause of mortality
within the first year after lung transplantation [1]. It clinically
manifests with progressive, severe hypoxaemia and pulmonary
infiltrates on chest X-ray (CXR) without other identifiable causative
lung pathology within the first 72 h after transplantation. It
encompasses a spectrum of acute lung injury ranging from milder
allograft dysfunction to more severe acute respiratory distress syn-
drome (ARDS). In 2005, a ‘PGD Working Group’ was summoned
by the International Society for Heart and Lung Transplantation
(ISHLT) that proposed a classification to standardize the definition
of the PGD. PGD grade 3 means PaO2=FIO2 in mmHg (P/F ratio)
<200 and diffuse allograft infiltrates on CXR within 72 h after lung
transplantation [2]. The incidence of PGD has been reported to be
at 10–30% [3]. PGD causes prolonged mechanical ventilation and
increased length of stay in the intensive care unit. PGD causes
worse functional outcome with an increased risk for the†Silvia R. Cottini and Ulrike E. Ehlers contributed equally to this work.
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development of chronic lung allograft dysfunction, particularly
bronchiolitis obliterans syndrome. Investigations that specifically
evaluate risk factors for PGD may influence the outcome in recipi-
ents undergoing lung transplantation [4].
The pathogenesis of PGD is complex and consequent to ischae-
mia–reperfusion injury resulting from direct damage of ischaemia
and preservation, generation of reactive oxygen species at reper-
fusion and activation of a damage-amplifying pro-inflammatory
cascade. Experimental and clinical evidence suggest that PGD
develops in a biphasic pattern with the early phase of PGD de-
pending primarily on cells presenting in the donor lung and the
later phase of PGD resulting from an influx of recipient cells [5].
The role of dys- and hyperlipidaemia as promoters of inflam-
mation is well known, i.e. during arteriosclerotic plaque development,
specially the antioxidant, antithrombotic and anti-inflammatory
properties of the high-density lipoprotein-cholesterol (HDL-C)
protect against atherogenesis [6, 7]. It is believed that the anti-
inflammatory nature of HDL-C could also be beneficial in other
inflammatory diseases as sepsis or rheumatoid arthritis [8, 9].
Inflammatory processes precede or develop at cerebral death
of the donor and follow the graft in subsequent phases of conser-
vation and surgery during lung transplantation [10–12]. We have
previously shown that pretransplant dyslipidaemia determines
outcome in lung transplant recipients [13], but up to now, the role
of lipids in lung patients has been poorly investigated. In parti-
cular, we still lack data on whether preoperative dyslipidaemia
affects the incidence of PGD.
In view of these circumstances, we hypothesized that preopera-
tive dyslipidaemia may influence the incidence of PGD after lung
transplantation.
MATERIALS ANDMETHODS
The study was approved by the local ethics committee (KEK-Nr.:
2014-0195). A systematic chart review of all consecutive lung
transplantations performed between 1 March 2000 and 31 October
2013 at the University Hospital Zurich was carried out. Since 1
March 2000, our centre has adopted and exclusively used low-
potassium dextran organ preservation solution.
We collected clinical and demographic data of 264 consecutive
patients over 13 years of age, receiving their first bilateral lung
transplant. Lipid profiles at transplantation assessment or just
before transplantation (baseline) were documented in a stan-
dardized fashion, including total cholesterol (Chol; normal value
<5 mmol/l), triglycerides (TGs; normal value <2 mmol/l), HDL-C
(normal value >1 mmol/l) and cholesterol/HDL-C ratio (normal
value <5). Dyslipidaemia was defined as any of the parameters
to be out of range. At the time of transplantation, none of our
patients received statins. Immunosuppression consisted of induc-
tion therapy with basiliximab, and maintenance therapy included
steroids, cyclosporine A and anti-metabolites (azathioprine or
mycophenolate mofetil) as previously described [14].
PGD grade 3 was diagnosed according to the ISHLT criteria [2].
Chest radiographs were obtained after transplantation and then
generally daily for 3 days. The PaO2=FIO2 ratio was measured
several times daily.
We further assessed currently known risk factors for PGD such
as body mass index (BMI), blood transfusion >1000 ml during
transplantation and the need of cardiopulmonary bypass (CPB) or
intraoperative extracorporeal membrane oxygenation (ECMO) as
well as the recipients’ underlying conditions.
At last, we analysed possible donor’s risk factors for PGD includ-
ing age, female sex and history of tobacco, as recently described
by Grimm et al. [15].
Data analysis
Descriptive statistics were presented as arithmetic means with
standard deviation (SD) for quantitative data and as absolute
numbers with percentages for qualitative data. Comparisons of con-
tinuous variables between patients with PGD grade 3 and those
without were performed with Student’s t-test, whereas proportions
were compared with the χ2 test or Fisher’s exact test as appropriate.
To identify PGD grade 3 risk factors, a logistic regression model was
used. PGD grade 3 was taken as the primary endpoint (outcome
variable). The following potential predictor variables were selected
and introduced in the logistic regression model in order to assess
the association with graft dysfunction: pretransplant dyslipidaemia
(yes versus no); intraoperative use of CPB or ECMO (yes versus no);
intraoperative blood transfusions >1000 ml (yes versus no) and re-
cipient BMI. Odds ratios (ORs) with the corresponding 95% confi-
dence intervals were then calculated. A P-value of <0.05 was
considered statistically significant. All analyses were performed
using IBM SPSS Statistics (version 22, IBM Corp., Armonk, NY, USA).
RESULTS
There were 264 consecutive first bilateral adult lung transplantations
performed at the University Hospital Zurich during the study period.
The mean patient age was 47 ± 15 years, with 44% female recipients
(n = 115). Patients’ clinical characteristics are presented in Table 1.
Of these, 63 subjects (24%) developed PGD grade 3. Blood
transfusions during surgery were required in 96 recipients (36%).
CPB or intraoperative ECMO were used in 112 recipients (42%),
both statistically more frequent in recipients with PGD. With
regard to the underlying condition, patients with chronic ob-
structive pulmonary disease (7 vs 77, P < 0.0005) and cystic fibrosis
(13 vs 67, P < 0.005) were significantly less likely to develop PGD.
Patients with PGD had significantly longer ischaemic time






Age (years) [mean ± SD] 48 ± 15 47 ± 15 0.71
Male, n (%) 33 (52) 106 (53) 0.96
BMI [mean ± SD] 23.4 ± 5.1 21.5 ± 4.3 0.0025
Diagnosis, n (%)
COPD 7 (11) 77 (38) 0.15
Other ILD 43 (68) 57 (28) <0.001
CF 13 (21) 67 (33) 0.39
CPB or ECMO 43 (68.3) 69 (34.3) <0.001
Ischaemic time (min)
[mean ± SD]
350 ± 89 322 ± 91 0.017
Blood transfusion
>1000 ml, n (%)
35 (55.5) 61 (30.3) <0.001
Dyslipidaemia, n (%) 45 (71.4) 108 (57.3) 0.013
PGD: primary graft dysfunction; BMI: body mass index; COPD: chronic
obstructive pulmonary disease; ILD: interstitial lung disease; CF: cystic
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(350 ± 89 vs 322 ± 91, P = 0.017) and higher BMI (23 ± 5 vs 21 ± 4.4,
P < 0.007). Dyslipidaemia was present in 153 recipients (58%).
Among subjects with PGD, dyslipidaemia was more prevalent
(45 vs 108, P = 0.023). Patients developing PGD had higher TG levels
(1.41 ± 0.78 vs 1.16 ± 0.78, P < 0.012), lower HDL-C concentrations
(1.24 ± 0.55 vs 1.57 ± 0.7163, P < 0.0005) and higher cholesterol/
HDL-C values (3.80 ± 2.02 vs 3.00 ± 0.92, P < 0.0005; Table 2).
To test for the importance of the individual risk factors of dyslipi-
daemia, requirement for CPB or ECMO therapy, elevated recipient’s
BMI and transfusion of >1000 ml of red cells, a logistic regression
model was generated. We found the requirements for ECMO and
red cell transfusion to be the strongest risk factors with an OR of >2,
pretransplant dyslipidaemia to be of intermediate risk (OR 1.9) and
an increased BMI to be a minor risk factor (OR 1.1; Table 3).
None of the cited donor risk factors were found to be statistical-
ly significant.
DISCUSSION
Our findings suggest dyslipidaemia to be an independent risk
factor for the development of the PGD after lung transplantation,
with low circulating levels of HDL-C and hypertriglyceridaemia
increasing the incidence of PGD. In the univariate analysis,
decreased levels of HDL-C showed the stronger association with
PGD, which may support our hypothesis of a possible modulation
of the inflammatory pathway modulated by the lipid status. The
protective effect of HDL-C in cardiovascular and inflammatory
diseases is the result of several beneficial functions [16]. There is
growing evidence that HDL-C can be modified and become dys-
functional during acute or chronic inflammatory states [17].
Among the few studies that have investigated the context of
lipids and inflammation in lung transplant recipients, Allen et al.
[18] demonstrated that lung transplant recipients with PGD grade
>2 had elevated pretransplant levels of pro-inflammatory cyto-
kines. In recipients with pulmonary arterial hypertension, Heresi
et al. observed a higher mortality and clinical deterioration asso-
ciated with depleted levels of HDL-C; however, none of these
patients underwent lung transplantation [19].
The limitations of our study are the retrospective character and
the limited number of recipients; nevertheless, this is the largest
cohort to date available, and thus, our data are important to initi-
ate further trials.
Even though the exact mechanism linking dyslipidaemia and
PGD cannot be explained, it seems suggestive in view of research
performed in other inflammatory diseases [6–9]. Thus, our data
are a valuable addition to the existing knowledge and could
trigger further research.
The documented association in our study was independent of
adjustment from multiple known confounding variables, and was
strongest with lower serum levels of HDL-C, fulfilling the concept
of linearity (i.e. stronger effect with a more pronounced risk
factor). Similar to other study populations, longer ischaemic time,
blood transfusions and the use of CPB or intraoperative ECMO re-
present independent risk factors for PGD after transplantation [3].
Even if HDL-C levels are difficult to alter today [20], TG and
cholesterol levels can be addressed therapeutically and may have
a positive influence on the development of PGD. These circum-
stances and possible further understanding of the complex mech-
anism of HDL-C would encourage further work in this area.
In summary, we identified dyslipidaemia, and especially low
HDL-C, as a risk factor for the development of PGD grade 3 after
lung transplantation in our study population.
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